ConductScience.org, home

Disease · HP_0100607

Drugs44

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
ETHINYL ESTRADIOLCHEMBL691Small moleculeApprovalPMDA191614Drugs and targets
DROSPIRENONECHEMBL1509Small moleculeApprovalPMDA1187Drugs and targets
IBUPROFENCHEMBL521Small moleculeApprovalDailyMed15964Drugs and targets
NAPROXENCHEMBL154Small moleculeApprovalDailyMed1453Drugs and targets
NORETHINDRONECHEMBL1162Small moleculeApprovalPMDA644Drugs and targets
DIENOGESTCHEMBL1201864Small moleculeApprovalPMDA544Drugs and targets
LEVONORGESTRELCHEMBL1389Small moleculeApprovalPMDA543Drugs and targets
NAPROXEN SODIUMCHEMBL1200806Small moleculeApprovalDailyMed and FDA6033Drugs and targets
MEFENAMIC ACIDCHEMBL686Small moleculeApprovalDailyMed and TTD1022Drugs and targets
ACETAMINOPHENCHEMBL112Small moleculeApprovalDailyMed422Drugs and targets
DICLOFENACCHEMBL139Small moleculeApprovalDailyMed311Drugs and targets
CELECOXIBCHEMBL118Small moleculeApprovalDailyMed400Drugs and targets
VALDECOXIBCHEMBL865Small moleculeApprovalEMA Human Drugs, at withdrawal300Drugs and targets
ASPIRINCHEMBL25Small moleculeApprovalDailyMed200Drugs and targets
BUTYLSCOPOLAMINECHEMBL1618102Small moleculeApprovalTTD100Drugs and targets
CLONIXINCHEMBL1332971Small moleculeApprovalTTD100Drugs and targets
FENTIAZACCHEMBL589092Small moleculeApprovalTTD100Drugs and targets
FLUFENAMIC ACIDCHEMBL23588Small moleculeApprovalTTD100Drugs and targets
KETOPROFENCHEMBL571Small moleculeApprovalDailyMed100Drugs and targets
MECLOFENAMATE SODIUMCHEMBL1562610Small moleculeApprovalDailyMed100Drugs and targets

diseases-2026-09-18-0.1.0

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/diseases/v1/HP_0100607/drugs